Hormonal
GLP-1 receptor agonist treatment alone, despite causing significant weight loss, does not improve physical functional performance or cardiorespiratory fitness compared to placebo.
Taking GLP-1 medication will help you lose weight, but it will not make you more physically fit or improve your ability to perform daily tasks. If you rely solely on medication, you may lose weight but not gain the stamina or functional strength that exercise provides. To improve fitness, you must add structured exercise.
Liraglutide alone did not improve the stair climb test performance compared with placebo (+ 0.46 s; 95% CI − 0.16, 1.08)... Liraglutide alone did not significantly improve cardiorespiratory fitness compared to placebo (2.3 mL/min/kg FFM [95% CI − 0.4, 4.9]).
Why this rating
RCT data showing no significant difference between liraglutide and placebo for fitness endpoints.
Source
Physical Fitness with Exercise and GLP-1 Receptor Agonist Treatment Alone or Combined After Diet-Induced Weight Loss: A Secondary Analysis of a Randomized Controlled Trial in Adults with Obesity
Simon Birk Kjær Jensen et al. · Sports Medicine · 2026
DOI 10.1007/s40279-025-02386-0
More from this paper
- Combined treatment with structured moderate-to-vigorous exercise and GLP-1 receptor agonist (liraglutide) significantly improves physical functional performance and cardiorespiratory fitness compared to pharmacotherapy alone, whereas pharmacotherapy alone fails to improve these fitness metrics despite weight loss.Good
- Exercise alone produces similar improvements in physical functional performance and cardiorespiratory fitness as the combined treatment of exercise and GLP-1 agonist, indicating that exercise is the primary driver of fitness gains independent of the pharmacotherapy.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →